Quick answer
What is Livagen?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
Livagen is a peptide, grouped on this site under Short peptide bioregulators, and the 12 research records kept here are 4 from studies in rats or mice and 8 that do not state what kind of study it is.
The literature search returned 18 records. This site keeps 12 of them, which is 67 per cent of what came back.
What it is
This site puts it in the Short peptide bioregulators group.
A tetrapeptide bioregulator; the retrieved records report chromatin activation in lymphocytes and inhibition of enkephalin-degrading enzymes, with no receptor target named.[1, 2]
Stated in the titles of the cited 2002 Bulletin of Experimental Biology and Medicine and 2003 Izvestiia Akademii Nauk papers.
What kind of records
The records kept here are animal and laboratory studies only.
That sentence is produced by counting, not by reading. What was counted: no interventional human trial record; 4 rodent and 0 in vitro records among 12.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 6 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of experimental biology and medicine (2002). pmid:12533768
- [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izvestiia Akademii nauk. Seriia biologicheskaia (2003). pmid:12942748